Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ADAMTS5 | Q9UNA0 | 4/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29385536 | 0.94 | KMT2A (0.43) | MEN1KMT2AALDH1A1MAPTHPGD | |
| SCHEMBL4565809 | 0.89 | MEN1 (0.40) | MEN1KMT2AALDH1A1MAPTHPGD | |
| SCHEMBL30679137 | 0.87 | NPC1 (0.44) | MEN1KMT2AALDH1A1MAPTHPGD | |
| SCHEMBL20973955 | 0.86 | NPC1 (0.40) | MEN1KMT2AALDH1A1MAPTHPGD | |
| SCHEMBL27082137 | 0.85 | NPC1 (0.40) | MEN1KMT2AALDH1A1MAPTHPGD | |
| SCHEMBL28191790 | 0.85 | NPC1 (0.39) | MEN1KMT2AALDH1A1MAPTHPGD | |
| SCHEMBL8752790 | 0.85 | NPC1 (0.41) | MEN1KMT2AHPGDLMNASMN1; SMN2 | |
| SCHEMBL28069714 | 0.83 | FABP5 (0.45) | MEN1KMT2AALDH1A1MAPTHPGD | |
| SCHEMBL31749265 | 0.82 | KMT2A (0.54) | MEN1KMT2AALDH1A1MAPTHPGD | |
| SCHEMBL27214060 | 0.82 | KMT2A (0.54) | MEN1KMT2AALDH1A1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4526323-A1 | MACROCYCLIC IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2025-03-26 | — | — | EP | disclosed |
| EP-4499667-A1 | MACROCYCLIC IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2025-02-05 | — | — | EP | disclosed |
| CN-119013287-A | Macrocyclic immunomodulators | 百时美施贵宝公司 | 2024-11-22 | — | — | CN | disclosed |
| EP-4441069-A1 | MACROCYCLIC IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2024-10-09 | — | — | EP | disclosed |
| CN-118613490-A | Macrocyclic immunomodulators | 百时美施贵宝公司 | 2024-09-06 | — | — | CN | disclosed |
| EP-4419540-A1 | IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2024-08-28 | — | — | EP | disclosed |
| CN-118159549-A | Immunomodulators | 百时美施贵宝公司 | 2024-06-07 | — | — | CN | disclosed |
| EP-4373835-A1 | MACROCYLIC IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2024-05-29 | — | — | EP | disclosed |
| CN-118076623-A | Macrocyclic immunomodulators | 百时美施贵宝公司 | 2024-05-24 | — | — | CN | disclosed |
| EP-4370530-A1 | MACROCYCLIC IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2024-05-22 | — | — | EP | disclosed |
| WO-2023069994-A1 | IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023004240-A1 | MACROCYLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-01-26 | — | — | WO | disclosed |
| WO-2023288213-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-01-19 | — | — | WO | disclosed |
| US-20220380425-A1 | ANGPTL3 BASED VACCINE FOR THE TREATMENT OF LIVER DISEASE | CADILA HEALTHCARE LIMITED (IN) | 2022-12-01 | — | — | US | disclosed |
| WO-2022204412-A1 | IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-09-29 | — | — | WO | disclosed |
| CN-109153703-B | Immunomodulator | 百时美施贵宝公司 | 2022-09-23 | — | — | CN | disclosed |
| CN-107428804-B | Immunomodulator | 百时美施贵宝公司 | 2022-06-28 | — | — | CN | disclosed |
| CN-114652813-A | Macrocyclic peptides as immunomodulators | 百时美施贵宝公司 | 2022-06-24 | — | — | CN | disclosed |
| EP-3993820-A1 | ANTIBODIES TO HUMAN PROGRAMMED DEATH RECEPTOR PD-1 | Cadila Healthcare Limited (IN) | 2022-05-11 | — | — | EP | disclosed |
| CN-107108698-B | Macrocyclic peptides as immunomodulators | 百时美施贵宝公司 | 2022-04-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220380425-A1 | ANGPTL3 BASED VACCINE FOR THE TREATMENT OF LIVER DISEASE | HDGFL3, PCSK9, TEK | MEN1 2806/4885KMT2A 3400/4885ALDH1A1 2836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.